Xinjiang Wu

Baseline urate level and renal function predict outcomes of urate-lowering therapy using low doses of febuxostat and benzbromarone: a prospective, randomized controlled study in a Chinese primary gout cohort

Changgui Li, L. Cui, Mingshu Sun, 2019, Arthritis Research & Therapy.

IBI303, a biosimilar to adalimumab, for the treatment of patients with ankylosing spondylitis in China: a randomised, double-blind, phase 3 equivalence trial.

Huji Xu, Ling Zhou, Ting Li, 2019, The Lancet Rheumatology.

Serum CA72-4 is specifically elevated in gout patients and predicts flares

Changgui Li, X. Bai, Xin-de Li, 2020, Rheumatology.

Clinical characteristics associated with subcutaneous tophi formation in Chinese gout patients: a retrospective study

Changgui Li, L. Cui, Zhen Liu, 2018, Clinical Rheumatology.

Urate‐lowering therapy alleviates atherosclerosis inflammatory response factors and neointimal lesions in a mouse model of induced carotid atherosclerosis

T. Merriman, Changgui Li, Mingshu Sun, 2019, The FEBS journal.

Uric acid lowering treatment alleviates perivascular carotid collar placement induced neointimal lesions in Uricase knockout mice

T. Merriman, Changgui Li, Mingshu Sun, 2018, bioRxiv.

Fresh Perspectives on the CARES Trial and the Use of Febuxostat in an Asian Population: Comment on the Article by Choi et al

Changgui Li, Xinjiang Wu, 2019, Arthritis & rheumatology.